The U.S. Food and Drug Administration recently awarded a three-year, $1.5 million grant to the American Dental Association Science & Research Institute (ADASRI) and the University of Pittsburgh to create guidelines for the management of acute pain in dentistry.
The partners will develop, disseminate, implement and evaluate a national clinical practice for pain management, improve clinician and patient access to information needed to make acute pain management decisions, and define the role of opioids in dentistry.
“As a part of the recently founded ADA Science & Research Institute, I believe that this project reflects the strong commitment of the ADASRI to conduct research on topics of great importance for the public and the dental profession,” said Dr. Carrasco-Labra, ADASRI’s department of Evidence Synthesis & Translation Research senior director and co-principal investigators of the project. “Getting this award is another effort in alignment with the strong response of the ADA to ensure the optimal management of acute pain in dentistry, including the use of opioid medications.”
The ADA previously issued a policy that dentists consider nonsteroidal anti-inflammatory analgesics as the first-line therapy for acute pain. In 2018, the association adopted a policy that supports prescription limits for opioids and made mandatory continuing education for dentists.